Biologics for Psoriasis: A Complete Guide to Treatment Classes

Biologic medications have transformed moderate-to-severe psoriasis treatment over the past two decades, but the sheer number of options and drug classes can be genuinely confusing. Here's a clear overview of how they differ.

What Biologics Actually Are

Unlike traditional oral medications, biologics are proteins — typically antibodies — manufactured to target specific parts of the immune system involved in driving psoriasis, rather than broadly suppressing immune function the way older systemic treatments (like methotrexate or cyclosporine) do. They're administered by injection or infusion, since as proteins, they'd be broken down by digestion if taken orally.

The Main Biologic Classes

TNF-alpha Inhibitors

The oldest biologic class for psoriasis, including adalimumab, etanercept, infliximab, and certolizumab. These block tumor necrosis factor-alpha, a broad inflammatory signaling molecule involved in multiple immune pathways. They have the longest track record of any biologic class, with extensive long-term safety data, though newer classes generally show higher response rates in head-to-head comparisons.

IL-12/23 Inhibitors

Ustekinumab blocks a shared protein subunit used by both IL-12 and IL-23, two cytokines involved in psoriasis inflammation. This was an important step toward more targeted treatment, offering the convenience of infrequent dosing (as few as 4 injections per year after initial doses).

IL-17 Inhibitors

Including secukinumab, ixekizumab, and brodalumab, these target IL-17, a cytokine central to the Th17 immune pathway that drives psoriasis. As covered in our article on treatment timelines, this class tends to show the fastest onset of clinical response among biologics.

IL-23 Inhibitors

Including guselkumab, risankizumab, and tildrakizumab, these target IL-23 specifically (rather than the shared subunit approach of IL-12/23 inhibitors), offering high response rates with relatively infrequent dosing — some require injections as rarely as every 12 weeks after initial doses.

How Doctors Choose Between Them

Selection typically depends on several factors: disease severity and specific presentation (some classes have stronger evidence for particular subtypes like scalp or nail involvement), whether psoriatic arthritis is also present (not all biologics are equally effective for joint symptoms), other health conditions (certain classes are avoided with specific comorbidities, like TNF-inhibitors in heart failure — see our cardiovascular risk article), dosing frequency preferences, and individual response, since not everyone responds identically to the same medication.

What They Have in Common

All biologics work by targeting a specific part of the immune signaling cascade rather than broadly suppressing immunity — this generally means a more favorable side-effect profile than older systemic treatments, though it also means a somewhat increased infection risk, since the immune system's ability to fight certain pathogens is partially affected. Regular monitoring, typically including screening for tuberculosis before starting treatment, is standard practice across all biologic classes.

Frequently Asked Questions

Are newer biologics always better than older ones?

Not necessarily "better" in every case — newer classes generally show higher average response rates in trials, but individual response varies, and the older TNF-inhibitor class has the longest track record for long-term safety monitoring.

Can I switch between biologic classes if one doesn't work?

Yes — switching between classes is common practice if a particular biologic isn't providing adequate response, and your dermatologist can help determine the most appropriate next option based on your specific situation.

Next Steps

For a detailed look at the newest oral option in this space, see our article on TYK2/JAK inhibitors.

This article is for general educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Biologic selection should always be made with your dermatologist based on your specific health profile.